Goldman Sachs Reaffirms Buy Rating for Johnson & Johnson

Goldman Sachs reaffirmed its Buy rating on Johnson & Johnson with a $265 price target as JNJ approaches its Q1 2026 earnings report. The analyst described 2025 as a 'banner year' for J&J's Innovative Medicines division, which staged a strong recovery following the loss of exclusivity on Stelara — one of pharma's largest patent cliffs — while MedTech stabilized after a challenging prior year. Goldman noted that new product cycles in oncology and immunology are underpinning expectations of sustained, accelerating growth through the rest of 2026.

The reaffirmation arrives as JNJ shares have outperformed the broader healthcare sector in 2026 year-to-date, with Goldman noting that the commercial momentum shift is driving a re-rating of the stock. The company's diversified business model — spanning pharmaceuticals, surgical technologies, and MedTech devices — provides insulation against individual product headwinds that have hurt more concentrated biopharma peers navigating patent cliffs or single-asset pipelines.

The key near-term catalyst is the Q1 earnings report, where execution on the new product cycle story will either reinforce Goldman's $265 target thesis or create room for disappointment. J&J's MedTech recovery trajectory is being closely watched, as the segment had underperformed sector peers in 2024 before beginning to stabilize — any signals of acceleration would be a significant positive for investor sentiment around JNJ.